Santiago Palacios

Summary

Affiliation: Instituto Palacios
Country: Spain

Publications

  1. ncbi request reprint Relevant results of the WHI study for the management of the menopause in Spain
    Santiago Palacios
    Maturitas 44:83-6. 2003
  2. ncbi request reprint The prescription of hormone replacement therapy in Spain: differences between general practitioners and gynaecologists
    Camil Castelo-Branco
    Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Maturitas 55:308-16. 2006
  3. ncbi request reprint Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism
    Santiago Palacios
    Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain
    Maturitas 55:297-307. 2006
  4. ncbi request reprint Spanish post-menopausal women's viewpoints on hormone therapy
    Camil Castelo-Branco
    Gynecology, Obstetrics and Neonatology Institute ICGON, Hospital Clinic Barcelona, Faculty of Medicine, University of Barcelona, Barcelona, Spain
    Maturitas 56:420-8. 2007
  5. doi request reprint Clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and risk factors for endometrial pathology, breast cancer, and cardiovascular disease
    Santiago Palacios
    Palacios Institute of Women s Health and Medicine, Madrid, Spain
    Menopause 20:852-9. 2013
  6. pmc Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study
    Esther Roura
    Cancer Epidemiology Research Program, Institut Català d Oncologia IDIBELL, CIBER ESP, RTICC, L Hospitalet de Llobregat, Barcelona, Catalonia, Spain
    BMC Infect Dis 12:145. 2012
  7. doi request reprint Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study
    Santiago Palacios
    Palacios Institute of Women s Health, Calle Antonio Acuña, 9, 28009 Madrid, Spain
    Maturitas 76:81-7. 2013
  8. pmc Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview
    Palacios Santiago
    Palacios Institute of Woman s Health, Antonio Acuña 9, 28009 Madrid, Spain
    ScientificWorldJournal 2012:846824. 2012
  9. doi request reprint EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis
    Santiago Palacios
    Palacios Institute of Woman s Health Antonio Acuna, Madrid, Spain
    Maturitas 71:194-8. 2012
  10. pmc Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis
    Claus Christiansen
    Center for Clinical and Basic Research, Ballerup, Denmark
    BMC Musculoskelet Disord 11:130. 2010

Collaborators

Detail Information

Publications51

  1. ncbi request reprint Relevant results of the WHI study for the management of the menopause in Spain
    Santiago Palacios
    Maturitas 44:83-6. 2003
  2. ncbi request reprint The prescription of hormone replacement therapy in Spain: differences between general practitioners and gynaecologists
    Camil Castelo-Branco
    Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Maturitas 55:308-16. 2006
    ..The purpose of this study was to determine the frequency with which hormone replacement therapy (HRT) was prescribed and to identify physician-related factors associated with the prescription of HRT in Spain...
  3. ncbi request reprint Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism
    Santiago Palacios
    Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain
    Maturitas 55:297-307. 2006
    ..This combination may therefore offer an alternative therapeutic option with additional benefits beyond current HRT agents for symptomatic post-menopausal women...
  4. ncbi request reprint Spanish post-menopausal women's viewpoints on hormone therapy
    Camil Castelo-Branco
    Gynecology, Obstetrics and Neonatology Institute ICGON, Hospital Clinic Barcelona, Faculty of Medicine, University of Barcelona, Barcelona, Spain
    Maturitas 56:420-8. 2007
    ....
  5. doi request reprint Clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and risk factors for endometrial pathology, breast cancer, and cardiovascular disease
    Santiago Palacios
    Palacios Institute of Women s Health and Medicine, Madrid, Spain
    Menopause 20:852-9. 2013
    ..GINERISK was designed to assess the clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and to establish the presence of other risk factors...
  6. pmc Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study
    Esther Roura
    Cancer Epidemiology Research Program, Institut Català d Oncologia IDIBELL, CIBER ESP, RTICC, L Hospitalet de Llobregat, Barcelona, Catalonia, Spain
    BMC Infect Dis 12:145. 2012
    ..The aim of the current study was to investigate socio-demographic, lifestyle, and medical factors for potential associations with cervical HPV infection in women undergoing cervical cancer screening in Spain...
  7. doi request reprint Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study
    Santiago Palacios
    Palacios Institute of Women s Health, Calle Antonio Acuña, 9, 28009 Madrid, Spain
    Maturitas 76:81-7. 2013
    ..To evaluate the clinical safety of bazedoxifene (BZA) on the reproductive tract in postmenopausal women with osteoporosis over 7 years...
  8. pmc Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview
    Palacios Santiago
    Palacios Institute of Woman s Health, Antonio Acuña 9, 28009 Madrid, Spain
    ScientificWorldJournal 2012:846824. 2012
    ....
  9. doi request reprint EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis
    Santiago Palacios
    Palacios Institute of Woman s Health Antonio Acuna, Madrid, Spain
    Maturitas 71:194-8. 2012
    ..This clinical guide provides the evidence for the clinical use of selective estrogen modulators (SERMs) in the management of osteoporosis in postmenopausal women...
  10. pmc Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis
    Claus Christiansen
    Center for Clinical and Basic Research, Ballerup, Denmark
    BMC Musculoskelet Disord 11:130. 2010
    ..We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis...
  11. doi request reprint Epidemiology of female sexual dysfunction
    Santiago Palacios
    Palacios Institute of Woman s Health, Madrid, Spain
    Maturitas 63:119-23. 2009
    ..To review the epidemiology and co-morbidity of female sexual dysfunction...
  12. doi request reprint Women's perception of the efficacy of a soy extract with probiotic: the M3 study
    Santiago Palacios
    Instituto Palacios de Salud y, Medicina de la Mujer, Madrid, Spain
    Gynecol Endocrinol 24:178-83. 2008
    ..To determine women's perception of soy extracts containing a probiotic on climacteric-related symptoms...
  13. pmc Advances in hormone replacement therapy: making the menopause manageable
    Santiago Palacios
    Palacios Institute of Women s Health, Calle Antonio Acuña, 9, 28009, Madrid, Espana
    BMC Womens Health 8:22. 2008
    ..The intention, dose and regimen of HRT need to be individualized, based on the principle of choosing the lowest appropriate dose in relation to the severity of symptoms and the time and menopause age...
  14. doi request reprint Patient scenario: a 53-year-old woman with hypoactive sexual desire disorder
    Santiago Palacios
    Palacios Institute of Woman s Health, Antonio Acuña, 9, 28009 Madrid, Spain
    Maturitas 63:164-8. 2009
    ..To provide an expert review of the clinical management of hypoactive sexual desire disorder...
  15. doi request reprint Managing urogenital atrophy
    Santiago Palacios
    Palacios Institute of Woman s Health, Madrid, Spain
    Maturitas 63:315-8. 2009
    ..Oestrogen given systemically or locally in all dosage regimens is effective, but topical vaginal application alone is preferred if systemic treatment is not needed. Treatment is long term and may be required for many years...
  16. doi request reprint Knowledge and compliance from patients with postmenopausal osteoporosis treatment
    Santiago Palacios
    Instituto Palacios, Madrid, Spain
    Menopause Int 15:113-9. 2009
    ..The aim of this study was to evaluate the knowledge, attitudes and expectations of patients receiving treatment for postmenopausal osteoporosis, analysing the factors related to good compliance with treatment...
  17. ncbi request reprint [Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine]
    Mariella Lilue
    Instituto Palacios de Salud y Medicina de la Mujer, Madrid, Espana
    Ginecol Obstet Mex 77:475-81. 2009
    ..To review the published data that include Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), especially desvenlafaxine, on vasomotor symptoms (VMS)...
  18. ncbi request reprint Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis
    Santiago Palacios
    Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain
    Curr Med Res Opin 26:1553-63. 2010
    ..This article reviews the clinical efficacy and safety data for bazedoxifene in postmenopausal women with or at risk for osteoporosis...
  19. doi request reprint The management of iron deficiency in menometrorrhagia
    Santiago Palacios
    Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain
    Gynecol Endocrinol 27:1126-30. 2011
    ..An extended-release formulation of ferrous sulphate with mucoproteose has been shown to be associated with a lower incidence of gastrointestinal adverse effects compared with other ferrous and ferric salts...
  20. doi request reprint Hypoactive Sexual Desire Disorder and current pharmacotherapeutic options in women
    Santiago Palacios
    Palacios Institute of Woman s Health, Antonio Acuña, 9, 28009, Madrid, Spain
    Womens Health (Lond Engl) 7:95-107. 2011
    ..Presently, new therapeutic strategies to combat HSDD are being researched, including novel methods of testosterone provision and drugs that act upon the CNS...
  21. doi request reprint Bazedoxifene acetate for the management of postmenopausal osteoporosis
    S Palacios
    Palacios Institute of Women s Health, Madrid, Spain
    Drugs Today (Barc) 47:187-95. 2011
    ..This has made this compound an appropriate option in young postmenopausal women with osteoporosis and a risk of fractures...
  22. ncbi request reprint Selective estrogen receptor modulators: the future in menopausal treatment
    S Palacios
    DPalacios Institute of Woman s Health Madrid, Spain
    Minerva Ginecol 63:275-86. 2011
    ..A long road to the ideal SERM still remains, but new SERMs represent an attractive new menopause treatment...
  23. ncbi request reprint The future of the new selective estrogen receptor modulators
    Santiago Palacios
    Palacios Institute of Women s Health, Antonio Acuña 9, 28009 Madrid, Spain
    Menopause Int 13:27-34. 2007
    ..Technological advances in the study of estrogen receptor activation will provide key information for drug development...
  24. ncbi request reprint Androgens and female sexual function
    Santiago Palacios
    Palacios Institute of Woman s Health, Madrid, Spain
    Maturitas 57:61-5. 2007
    ....
  25. ncbi request reprint [Role of sildenafil in female sexual dysfunction]
    S Palacios Gil-Antuñano
    Instituto Palacios, Salud y Medicina de la Mujer, Madrid
    Rev Clin Esp 204:483-5. 2004
  26. ncbi request reprint The 'Million Women' Study should not change HRT prescription
    Santiago Palacios
    President of the Spanish Menopause Society and Director of Instituto Palacios of Women s Health, Jorge Juan 36, 28001 Madrid, Spain
    Maturitas 46:97-8. 2003
  27. ncbi request reprint [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]
    Santiago Palacios
    Instituto Profesor Palacios, SL Madrid, Espana
    Med Clin (Barc) 122:205-11. 2004
    ..There are numerous health-related quality of life questionnaires but only a few are specific for the menopause. The objective of this study was to develop and validate a specific scale, the Cervantes Scale, for menopause in Spanish women...
  28. ncbi request reprint The importance of preventive health care in post-menopausal women
    S Palacios
    Instituto Palacios of Woman s Health, Calle Antonio Acuña 9, 28009 Madrid, Spain
    Maturitas 52:S53-60. 2005
    ..Physicians should therefore search for patients with risk factors for these diseases. Prevention and treatment to avoid medical accidents will improve the quantity and quality of life...
  29. ncbi request reprint Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy
    Santiago Palacios
    Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain
    Maturitas 50:98-104. 2005
    ..Thus, in order to obtain a prompt improvement, the association of local therapy acting on the genital epithelium to the systemic treatment should be considered...
  30. ncbi request reprint Endometrial safety assessment of a specific and standardized soy extract according to international guidelines
    Santiago Palacios
    Instituto Palacios, Madrid, Spain
    Menopause 14:1006-11. 2007
    ..To assess the effects of an oral soy isoflavone extract (Phytosoya) on endometrium (evaluated by biopsy and ultrasonography) in postmenopausal women treated for 12 months...
  31. doi request reprint Recommendations on the management of fragility fracture risk in women younger than 70 years
    Santiago Palacios
    Instituto Palacios, Salud y Medicina de la Mujer, C Antonio Acuña, Madrid, Spain
    Gynecol Endocrinol 28:770-86. 2012
    ..That is because it should be used in cases where the formation is greatly diminished and there is a high risk for fracture, something found in much older women...
  32. ncbi request reprint [WHI study on the attention of menopause in Spain: significance of its results]
    Santiago Palacios
    Instituto Palacios Antonio Acuña, 9 Local 28009 Madrid España
    Med Clin (Barc) 120:146-7. 2003
  33. doi request reprint Tolerability of different oral iron supplements: a systematic review
    María Jesús Cancelo-Hidalgo
    Universidad de Alcala, Alcala de Henares, Madrid, Spain
    Curr Med Res Opin 29:291-303. 2013
    ....
  34. ncbi request reprint Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial
    Santiago Palacios
    Institute Palacios of Woman s Health, Madrid, Spain
    Menopause 12:63-8. 2005
    ..To assess the effect of calcium, phosphorus, lactose, and vitamin D fortified skimmed milk on biomarkers of bone turnover in healthy postmenopausal women...
  35. ncbi request reprint Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate
    Santiago Palacios
    Instituto Palacios, Madrid, Spain
    Am J Obstet Gynecol 191:121-31. 2004
    ..This study was undertaken to provide a detailed evaluation of the potential of raloxifene to induce or exacerbate hot flushes in postmenopausal women...
  36. doi request reprint Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate
    Santiago Palacios
    Instituto Palacios, Madrid, Spain
    Menopause 19:67-74. 2012
    ..The aim of this study was to assess the factors associated with the effectiveness of treatment with alendronate (ALN) quantified by a reduction in urinary excretion of N-telopeptide (NTx)...
  37. doi request reprint Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial
    Santiago Palacios
    Instituto Palacios de Salud y Medicina de la Mujer, Madrid, Spain
    Eur J Obstet Gynecol Reprod Biol 149:57-62. 2010
    ..76 mg of 17beta-oestradiol) and dienogest (DNG) has been developed. The efficacy and safety of this formulation was assessed in the current study...
  38. ncbi request reprint Neuroprotective effects of soy phytoestrogens in the rat brain
    Inigo Azcoitia
    Departamento de Biologia Celular, Facultad de Biologia, Universidad Complutense, Madrid, Spain
    Gynecol Endocrinol 22:63-9. 2006
    ..Genistein showed neuroprotective effects only at high dose (10 mg/kg), suggesting that other components in the soy extract are involved in the neuroprotective effect...
  39. ncbi request reprint Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route
    Pierre D Delmas
    INSERM Research Unit 403 and Claude Bernard University, Pavillon F, Hopital E Herriot, 69437 Lyon, Cedex France
    Maturitas 48:85-96. 2004
    ..To compare the efficacy of pulsed estrogen therapy following intranasal 17beta-estradiol (E2) (S21400) with patch E2 in preventing postmenopausal bone loss and on bone turnover...
  40. ncbi request reprint Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study
    Camil Castelo-Branco
    Institute Clinic of Gynecology, Obstetrics, and Neonatology, Hospital Clinic, Faculty of Medicine University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Fertil Steril 88:383-9. 2007
    ..To evaluate the effect of intranasal continuous combined hormone therapy on serum lipids and leptin levels in healthy postmenopausal women...
  41. ncbi request reprint Menopausal transition in Movima women, a Bolivian Native-American
    Camil Castelo-Branco
    Institut Clinic de Ginecologia, Obstetricia i Neonatologia, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Maturitas 51:380-5. 2005
    ..Although it is well accepted that socio-cultural influences may affect the onset of menopause and the symptoms experienced, there are scant data related to native indigenous populations...
  42. doi request reprint Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial
    Esme A Nijland
    University Medical Center Groningen, Department of Psychosomatic Obstetrics and Gynaecology, Groningen, The Netherlands
    J Sex Med 5:646-56. 2008
    ..There are some data to suggest that tibolone improves sexual function in postmenopausal women. However, evidence about the effects of tibolone on female sexual dysfunction is lacking...
  43. doi request reprint Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy
    Johannes Bitzer
    University Women s Hospital Basel, Department of Gynecological Social Medicine and Psychosomatic, Spitalstrasse 21, 4031 Basel, Switzerland
    Maturitas 59:209-18. 2008
    ..The purpose of this study is to review the available clinical data on the impact of exogenous testosterone containing postmenopausal hormone therapy on breast cancer risk...
  44. ncbi request reprint [General recommendations over perimenopausal transition therapy]
    José Luis Neyro
    Servicio de Obstetricia y Ginecologia, Hospital de Cruces Baracaldo, Universidad del Pais Vasco, UPV EHU
    Ginecol Obstet Mex 75:573-81. 2007
    ..Medical attention during perimenopause requires different therapeutic strategies...
  45. ncbi request reprint Available medical choices for the management of menopause
    Camil Castelo-Branco
    Institut Clinic de Ginecologia, Obstetricia i Neonatologia, Clinic, Facultad de Medicina, Universidad de Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Maturitas 52:S61-70. 2005
    ..Gynaecologists and other health professionals would be advised to develop intervention strategies at menopause according to the continuum of a woman's life, beginning at the post-menarche and extending into later life...
  46. ncbi request reprint [Management of cardiovascular risk in the peri-menopausal woman--a consensus statement of European cardiologists and gynaecologists]
    Peter Collins
    NHLI, Imperial College London, Royal Brompton Hospital, London, Wielka Brytania
    Kardiol Pol 65:1331-46; discussion 1347-49. 2007
  47. ncbi request reprint [Substitutive hormonal treatment guidelines and risk of endometrial cancer. Data from the Million Women Study]
    Santiago Palacios
    Med Clin (Barc) 125:374-5. 2005
  48. ncbi request reprint Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women
    José I Martínez-Ferrandis
    Laboratorio de Genetica Molecular, Centro de Investigacion Principe Felipe, Valencia, Spain
    Cancer Biomark 3:89-93. 2007
    ..A decreased efficiency of DcR2 to work as decoy receptor for TRAIL, would facilitate the apoptotic pathway in cells at risk...
  49. ncbi request reprint Management of the a-symptomatic postmenopausal woman
    Santiago Palacios
    Maturitas 52:S1-2. 2005
  50. ncbi request reprint Practical recommendations for hormone replacement therapy in the peri- and postmenopause
    Henry Burger
    Climacteric 7:210-6. 2004
  51. ncbi request reprint Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists
    Peter Collins
    NHLI, Imperial College London, Royal Brompton Hospital, Dovehouse Street, London SW3 6LY, UK
    Eur Heart J 28:2028-40. 2007
    ....